TITLE: REPUPOSING OF CYCLIN DEPENDENT KINASE INHIBITOR ABEMACICLIB FOR STROCK TREATMENT
AUTHOR(S): Tejaswini Maruti Biraje*, Ishwari Ashok Nimbalka, Ashlesha Sanjay Navale, Prathamesh Amar Patil, Shonak Sandeep Adivarekar, Nikita Gangaram Tuppekar, Dr. Udugade Vithal Babaso.
Abstract:
This review examines the repurposing of established pharmacotherapies for the treatment of ischemic stroke, specifically ticagrelor and abemaciclib. Ticagrelor, reacts to platelet responsibility and increases cerebral blood flow, 1.000 dependent ligand is confirmed, ABEMACICLIB-Dick Strong bondage-attraction shows, indicating its ability to modulate Galactosidase Alpha activity, suitable for conditions that can complicate stroke outcomes Analysis also reveals promising strategies, including cangrelor and tedizolid, suggesting a diverse range of therapies to improve stroke management Structural analysis of protein-ligand interactions Provide insights into manufacturing optimization about and highlights the effectiveness of existing drugs in new clinical settings Findings advocate further experimental verification of the efficacy and safety of these recycled drugs in clinical practice, and ultimately aimed at improving patient outcomes in dementia care.
Keywords:
Stroke, Ticagrelor, Abemaciclib, Drug Reuse, P2Y12 Receptor Antagonist, Galactosidase Alpha, Molecular Docking, Virtual Screening, Treatment Seekers
Introduction:
A stroke is a serious medical condition defined as a sudden interruption of blood flow to the brain, resulting in immediate neurological damage that can affect movement, speech, and cognitive function[1].Types of strokes there are two main types: ischemic and hemorrhagic [2] . Accounts for about 87%, when it occurs when blood vessels supplying blood to the brain is damaged, due to local thrombus in a blood vessel or embolism or embolism , bleeding in body in other parts of the In contrast, blood vessels in the brain rupture, leading to hemorrhage and increased intracranial pressure and ischemia; This condition can also be divided into subarachnoid hemorrhage, where bleeding occurs in the space around the brain, and intracranial hemorrhage, where bleeding occurs within the brain capillaries themselves, major causes of mortality and longevity occurs worldwide[3] .The World Health Organization estimates that measles kills 5 million people each year, permanently 50 others in the form of It disables one million people and affects 15 million people each year as a fifth disease most common in the United States of epilepsy emphasizes the high immediate health costs and the need for effective treatment and prevention strategies[4].
Current treatment options for stroke focus primarily on restoring blood flow and preventing further nerve damage. Major therapies include thrombolytic therapy, such as recombinant tissue plasminogen activator (tPA), which is used to pop clots in acute bleeding episodes but tPA must be administered over a limited period of time—frequently most within 3 to 4.5 hours of symptom onset—to be effective in many patients[5] . Use is limited Mechanical thrombectomy is an alternative that involves physically removing large blood vessels and has proven effective for specific patients with major ischemic stroke[6] . Furthermore, antiplatelet agents such as aspirin and clopidogrel are commonly used for secondary prevention reduce the risk of stroke recurrence[7]. Limitations of there is a need; Many patients do not have access to emergency clinics for timely intervention, in contrast to tPA in hemorrhage. Furthermore, advanced interventional techniques such as thrombectomy are generally limited, especially in rural or underserved areas [8]. These challenges underscore the critical need for alternative therapies that can be delivered safely and effectively regardless of time or patient status[9].
Abemaciclib, a cyclin-based kinase inhibitor, offers a convenient recycling strategy in this regard. Bemaciclib, a specific inhibitor of CDK4 and CDK6, is used to treat hormone receptor positive breast cancer [10]. Abemaciclib disrupts the cell cycle by inhibiting these kinases, leading to cancer cell apoptosis and cell cycle arrest [11]. But emerging research suggests that abemaciclib may have neuroprotective effects due to its ability to modulate cellular processes associated with inflammation and apoptosis, which are important in stroke [12]. Preliminary studies, suggested that inhibitory drugs. The CDK edge will promote neuronal survival and neurodegenerative diseases and reduced inflammatory responses in injury models, suggesting potential applications in trauma therapy [13].
The aim of this study is to evaluate the efficacy of abemaciclib as a neuroprotective therapy in stroke, with a focus on the effects of neurogenesis and functional recovery in preclinical models 9140. We assume that abemaciclib administration would significantly reduce vascular cell death in ischemic stroke models compared to controls. Improvements in neuronal function and behavioral outcomes, and these neuroprotective effects are mediated by modulation of cell cycle regulatory pathways, and this reduction in turn leads to an inflammatory response in the brain. This study may pave the way for new therapeutic strategies in the management of stroke, ultimately improving patient outcomes.
Reference:
[1] Saceleanu VM, Toader C, Ples H, Covache-Busuioc RA, Costin HP, Bratu BG, Dumitrascu DI, Bordeianu A, Corlatescu AD, Ciurea AV. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. 2023 Sep 23; 11(10):2617.doi:10.3390/biomedicines11102617
[2] Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke se verity, mortality, and risk factors Stroke. 2009 Jun 1; 40(6):2068-72,doi:10.1161/STROKEAHA.108.540112
[3]Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology. 2013 Jan 15; 80(3_supplement_2):S5-12.doi:10.1212/WNL.0b013e3182762397
[4] Tento T, Kume A, Kumaso S. Risk factors for stroke-related functional disability and mortality at Felege Hiwot Referral Hospital, Ethiopia. BMC neurology. 2023 Oct 31;23(1):393.doi:10.1186/s12883-023-03444-8
[5] Zivin JA. Acute stroke therapy with tissue plasminogen activator (TPA) since it was approved by the US Food and Drug Administration (FDA). Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2009 Jul; 66(1):6-10doi:10.1002/ana.21750
[6] Krishnan R, Mays W, Elijovich L. Complications of mechanical thrombectomy in acute ischemic stroke. Neurology. 2021 Nov 16; 97(20_Supplement_2):S115-25.doi:10.1212/WNL.0000000000012803
[7] Shulga O, Bornstein N. Antiplatelets in secondary stroke prevention. Frontiers in neurology. 2011 Jul 4; 2:36.doi:10.3389/fneur.2011.00036
[8] Ospel JM, Diprose WK, Ganesh A, Martins S, Nguyen T, Psychogios M, Mansour O, Al-Ajlan F, Yang P, Pandian J, Gopinathan A. Challenges to widespread implementation of stroke thrombectomy. Stroke. 2024 Aug; 55(8):2173-83.doi:10.1161/STROKEAHA.124.045889
[9]Wick KD, McAuley DF, Levitt JE, Beitler JR, Annane D, Riviello ED, Calfee CS, Matthay MA. Promises and challenges of personalized medicine to guide ARDS therapy. Critical Care. 2021 Dec; 25:1-5.doi:10.1186/s13054-021-03822-z
[10] Hendrychová D, Jorda R, Kryštof V. How selective are clinical CDK4/6 inhibitors. Medicinal Research Reviews. 2021 May; 41(3):1578-98.doi:10.1002/med.21769
[11]Wander SA, O’Brien N, Litchfield LM, O’Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in cancer therapy: emerging preclinical insights related to abemaciclib. The oncologist. 2022 Oct 1; 27(10):811-21.doi:10.1093/oncology/oyac138
[12]Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O, Elgokhy T, Do T, Gann M, Martin R, Liu DZ. FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders. Pharmaceutical. 2022 Dec 13; 15(12):1546.doi:10.3390/ph15121546
[13] Łukasik P, Załuski M, Gutowska I. Cyclin-dependent kinases (CDK) and their role in diseases development–review. International journal of molecular sciences. 2021 Mar 13; 22(6):2935.doi:10.3390/ijms22062935
[14]Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O, Elgokhy T, Do T, Gann M, Martin R, Liu DZ. FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders. Pharmaceuticals. 2022 Dec 13; 15(12):1546.doi:10.3390/ph15121546
[15] Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiology in review. 2011 Mar 1; 19(2):95-100.DOI: 10.1097/CRD.0b013e3182099d86
[16] Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J. PubChem substance and compound databases. Nucleic acids research. 2016 Jan 4; 44(D1):D1202-13.doi.org/10.1093/nar/gkv951
[17] Avram S, Bologa CG, Holmes J, Bocci G, Wilson TB, Nguyen DT, Curpan R, Halip L, Bora A, Yang JJ, Knockel J. DrugCentral 2021 supports drug discovery and repositioning. Nucleic acids research. 2021 Jan 8; 49(D1):D1160-9. doi.org/10.1093/Nar/gkaa997
[18] Martin L. State of the art iterative docking with logistic regression and Morgan fingerprints. D O I: 10.26434/chemrxiv.14348117.
[19] de Vries I, Perrakis A, Joosten RP. PDB‐REDO in Computational‐Aided Drug Design (CADD). Open Access Databases and Datasets for Drug Discovery. 2024 Feb 5:201-29. doi.org/10.1002/9783527830497
[20] Liu Y, Cao Y. Protein–Ligand Blind Docking Using CB-Dock2. In Computational Drug Discovery and Design 2023 Sep 8 (pp. 113-125). New York, NY: Springer US.doi.org/10.1007/978-1-0716-3441-7_6
